Treatment of Dopaminomimetic Psychosis in Parkinson’s Disease with Electroconvulsive Therapy

T.A. Hurwitz, D.B. Calne and K. Waterman

ABSTRACT: Two Parkinsonian patients with chronic nonconfusional dopaminomimetic psychosis were treated with a course of electroconvulsive therapy. In both cases sustained remission of psychosis was obtained in the face of ongoing administration of dopaminomimetics.

RESUME: Traitement de la psychose dopaminomimetique par sismotherapie dans la maladie de Parkinson. Deux patients parkinsoniens, atteints de psychose dopaminomimetique chronique sans confusion, ont ete traites par sismotherapie. Dans les deux cas, une remission prolongee a ete obtenue malgre le maintien de la therapie dopaminomimetique.


Longterm levodopa or bromocriptine therapy in patients with Parkinson’s Disease may produce a variety of disabling psychiatric syndromes which includes restless agitation, hypomania, anxiety, hypersexual behaviour, and psychosis. A psychosis may occur in the presence or absence of confusion and usually responds to a dose reduction or drug withdrawal. In some patients this will lead to life threatening immobility. Any attempt to restart dopaminomimetics may lead to a recurrence of symptoms. The clinician is left with the unenviable choice of maintaining a patient mobile and mad or sane but unable to move. Neuroleptics may be administered but their dopamine blocking properties lead to deterioration in motor function. Electroconvulsive therapy (ECT) is of potential benefit in these circumstances since it has proven efficacy in other psychoses and has been shown to decrease some cases of Parkinsonian disability.

METHOD

Two patients with chronic nonconfusional dopaminomimetic psychosis were treated with a course of bilateral ECT after informed written consent was obtained from the patients and their families. The protocol had been approved by the University and Hospital Ethics Committees. Both patients were receiving dopaminomimetic drugs but no other antiparkinsonian medication. They had been psychotic for several months despite repeated attempts to lower their dose of dopaminomimetics. They were rated weekly on the Columbia Scale for Parkinsonian Disability (higher scores indicating increasing disability), the Brief Psychiatric Rating Scale with the item for motor retardation eliminated (higher scores indicating increasing mental disturbance), and the Mini-Mental State (higher scores indicating normal intellectual function with a maximum score of 30). Assessments were performed prior to, during and subsequent to the course of ECT. Over the period of ECT the dose of dopaminomimetics was kept constant. Following ECT the doses of medications were raised to optimize mobility.

CASE REPORTS

Case 1. A woman aged 66 years, with a seventeen year history of Parkinson’s disease (Hoehn and Yahr Stage V) presented with a seven month history of a paranoid and depressive psychosis. She had been on Sinemet for the preceding twelve years and was on Sinemet and bromocriptine at the time of admission. She had no previous psychiatric illness but had a positive family history for psychiatric disorder. Her psychosis was characterized by persistent, mood incongruent auditory hallucinations, occasional visual and somatic hallucinations, visual illusions, delusions of guilt, and delusions of reference and control. These phenomena occurred in the setting of depression, intermittent severe anxiety, obsessional ideas about sex, anergy, weeping, moderate hopelessness and global insomnia. Bedside evaluation of higher intellectual functions were within normal limits and her Mini-Mental State score was twenty-nine. She was wheelchair bound because of bilateral hip and leg contractures. Her initial Columbia score was 40.
disorder. His psychosis was characterized by global insomnia, thought delusions that would change from day to day. The delusions were based upon thought insertion and mood incongruent auditory hallucinations. The psychosis usually evolves out of a background of sleep disruption, vivid dreams and hallucinations. It may ultimately progress to a confusional psychosis although confusion is more likely to occur in patients with some pre-existing impairment of intellectual function.

Levodopa psychosis has been attributed to dopamine induced alterations in central serotonin activity. In patients dying with l-dopa psychosis, elevated levels of serotonin have been reported predominantly in the red nucleus but also in the raphe nuclei and the globus pallidus. Elevated levels may be due to displacement of serotonin from serotonergic neurons by l-dopa: this would alter the dopamine-serotonin balance and perhaps trigger the psychosis. However drugs that increase or decrease serotonergic transmission do not have any consistent effect on l-dopa psychosis.

L-dopa psychosis has also been attributed to agonist induced hypersensitivity of the postsynaptic dopamine receptors. Chronic stimulation of dopamine receptor sites has been claimed to induce supersensitivity of the postsynaptic dopamine receptors in rats and guinea pigs as shown by a decrease in the threshold and latency of onset of stereotypic behaviours to apomorphine (a direct dopaminomimetic) and d-amphetamine (an indirect dopaminomimetic). Similar ‘innervation’ induced dopamine receptor hypersensitivity has been reported for bromocriptine. Post-synaptic receptor hypersensitivity has also been postulated to be responsible for dopaminomimetic dyskinesias which, like the psychosis, occurs after longterm treatment. Indeed, dyskinesias and psychosis frequently co-exist. In psychosis, hypersensitivity may involve the mesolimbic dopamine projection. This mechanism is supported by the beneficial effect of clozapine and fluperoxipine in dopaminomimetic psychosis. Both these drugs are D2 blocking agents that preferentially bind to mesolimbic, mesocortical and hippocampal D2 receptors with no substantial binding to striatal dopamine receptors. The use of clozapine and fluperoxipine in dopaminomimetic psychosis is limited because of the risk of agranulocytosis.

The central importance of dopaminomimetics agents for the development of the psychosis is undoubtedly. Withdrawal or dose reduction will often allow the psychosis to remit. It is also possible to treat the psychosis with neuroleptics at the risk of exacerbating the underlying Parkinsonian disability. In our two cases restitution to a normal mental state by a course of ECT was sustained over several months in the face of an increased dose of dopaminomimetics. Thus dopaminomimetic psychosis may be due to a functional alteration in dopamine receptors that is reversible by ECT.

**DISCUSSION**

Nonconfusional dopaminomimetic psychosis usually occurs after longterm dopaminomimetic therapy although it may present within a few weeks of starting treatment in patients with pre-existing psychiatric disorders. Approximately 3% of patients treated with l-dopa for more than two years will develop this complication. The most common presentation is a paranoid psychosis. The psychosis usually evolves out of a background of sleep disruption, vivid dreams and hallucinations. It may ultimately progress to a confusional psychosis although confusion is more likely to occur in patients with some pre-existing impairment of intellectual function.

Levodopa psychosis has been attributed to dopamine induced alterations in central serotonin activity. In patients dying with l-dopa psychosis, elevated levels of serotonin have been reported predominantly in the red nucleus but also in the raphe nuclei and the globus pallidus. Elevated levels may be due to displacement of serotonin from serotonergic neurons by l-dopa: this would alter the dopamine-serotonin balance and perhaps trigger the psychosis. However drugs that increase or decrease serotonergic transmission do not have any consistent effect on l-dopa psychosis.

L-dopa psychosis has also been attributed to agonist induced hypersensitivity of the postsynaptic dopamine receptors. Chronic stimulation of dopamine receptor sites has been claimed to induce supersensitivity of the postsynaptic dopamine receptors in rats and guinea pigs as shown by a decrease in the threshold and latency of onset of stereotypic behaviours to apomorphine (a direct dopaminomimetic) and d-amphetamine (an indirect dopaminomimetic). Similar ‘innervation’ induced dopamine receptor hypersensitivity has been reported for bromocriptine. Post-synaptic receptor hypersensitivity has also been postulated to be responsible for dopaminomimetic dyskinesias which, like the psychosis, occurs after longterm treatment. Indeed, dyskinesias and psychosis frequently co-exist. In psychosis, hypersensitivity may involve the mesolimbic dopamine projection. This mechanism is supported by the beneficial effect of clozapine and fluperoxipine in dopaminomimetic psychosis. Both these drugs are D2 blocking agents that preferentially bind to mesolimbic, mesocortical and hippocampal D2 receptors with no substantial binding to striatal dopamine receptors. The use of clozapine and fluperoxipine in dopaminomimetic psychosis is limited because of the risk of agranulocytosis.

The central importance of dopaminomimetics agents for the development of the psychosis is undoubtedly. Withdrawal or dose reduction will often allow the psychosis to remit. It is also possible to treat the psychosis with neuroleptics at the risk of exacerbating the underlying Parkinsonian disability. In our two cases restitution to a normal mental state by a course of ECT was sustained over several months in the face of an increased dose of dopaminomimetics. Thus dopaminomimetic psychosis may be due to a functional alteration in dopamine receptors that is reversible by ECT.

The effect of ECT on dopamine receptors is controversial. Modigh et al have recently reviewed all the in vivo animal data and conclude that ECT increases the responsiveness of the postsynaptic dopamine receptors whereas the responsiveness of the presynaptic dopamine receptors is decreased. They and others have shown that ECT may improve Parkinsonian disabil-

---

**Table: Hospitalization Course**

<table>
<thead>
<tr>
<th>Case</th>
<th>Hospitalization Course</th>
<th>Week</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Hospitalization Course - Case 1</td>
<td>1-8</td>
<td>Score</td>
</tr>
<tr>
<td>2</td>
<td>Hospitalization Course - Case 2</td>
<td>1-6</td>
<td>Score</td>
</tr>
</tbody>
</table>
ity suggesting that ECT enhances postsynaptic dopamine receptor responsiveness.\textsuperscript{2,7,8,9,10,29,30,31} This benefit was not however, confirmed by Ward et al.\textsuperscript{32} Moreover in rats, ECT prevents haloperidol induced dopamine receptor hypersensitivity.\textsuperscript{33} These conflicting data are difficult to reconcile with our observations and raise the possibility that, in dopaminomimetic psychoses, ECT may be producing its effect via non-dopaminergic mechanisms.

Although our experience is limited to two patients, we consider that ECT may be a useful treatment in dopaminomimetic psychoses. Further study of ECT in dopaminomimetic psychosis is desirable to extend these preliminary observations.

REFERENCES